Lactulose fails to deliver results more often than most people expect, and the right next step depends entirely on why you’re taking it. For constipation, the fix might be as simple as switching to a different osmotic laxative or as involved as retraining the muscles you use to have a bowel movement. For hepatic encephalopathy, the problem often traces back to adherence issues, untreated infections, or the need for a second medication alongside lactulose. In either case, “not working” is a signal to investigate the cause rather than just increase the dose indefinitely.
Make Sure the Dose Is Actually Right
Before concluding that lactulose has failed, it’s worth confirming that the dose and timing are where they need to be. For constipation, a typical adult dose ranges from 15 to 30 mL once or twice daily, but some people need several days of consistent use before seeing results. Lactulose works by drawing water into the bowel and feeding gut bacteria that produce acids to soften stool. That process isn’t instant. If you’ve been taking it for less than 48 to 72 hours, it may simply need more time.
For hepatic encephalopathy, the dosing target is more specific: you’re aiming for two to three soft bowel movements per day. Clinicians titrate the dose up or down to hit that target, sometimes using stool consistency as a guide. One research group even developed a smartphone application that uses the Bristol Stool Scale to help patients and providers fine-tune lactulose dosing for hepatic encephalopathy.1PubMed. Artificial Intelligence-Enabled Stool Analysis for Lactulose Titration Assistance in Hepatic Encephalopathy Through a Smartphone Application The point is that a single fixed dose often isn’t enough. If you haven’t tried adjusting upward under medical guidance, that’s the first conversation to have.
Why Lactulose Fails for Constipation
When lactulose doesn’t relieve constipation, the most overlooked explanation is that the constipation isn’t caused by what lactulose treats. Lactulose softens stool and increases the water content in your colon. That helps if your stools are hard and dry. But roughly a third of people with chronic constipation have a coordination problem called pelvic floor dyssynergia, where the muscles that should relax during a bowel movement actually tighten. No amount of softening the stool fixes that. A randomized trial found that patients with this condition who were given laxatives fared poorly compared to those who received biofeedback training to retrain those muscles.2Gastroenterology. Biofeedback Is Superior to Laxatives for Normal Transit Constipation Due to Pelvic Floor Dyssynergia
Other causes of lactulose-resistant constipation include slow-transit constipation, where the colon itself moves contents too sluggishly, and secondary constipation caused by medications (opioids, calcium channel blockers, iron supplements, certain antidepressants) or medical conditions like hypothyroidism and diabetes. Clinical guidelines recommend that when first-line laxatives fail, the next step is to rule out these secondary causes and then determine whether the problem is a motility disorder or a coordination disorder, because the treatments diverge sharply from there.3PubMed Central. Evidence-Based Clinical Guidelines for Chronic Constipation 2023
Switching to Polyethylene Glycol
If you’re taking lactulose for constipation and it isn’t doing enough, the most straightforward swap is polyethylene glycol (PEG), sold over the counter under brand names like MiraLAX and others. A Cochrane systematic review that pooled data from studies in both adults and children concluded that PEG outperformed lactulose on stool frequency per week, stool form, abdominal pain relief, and the need for additional products.4PubMed Central. Lactulose versus Polyethylene Glycol for Chronic Constipation The review’s authors stated that PEG should be used in preference to lactulose for chronic constipation.
In children specifically, one trial found that PEG increased stool frequency more than lactulose at both one and three weeks, and that children on lactulose experienced significantly more abdominal cramps.5Journal of Shahrekord University of Medical Sciences. Polyethylene glycol versus lactulose in the treatment of chronic functional constipation in children: A randomized clinical trial For pregnant people, a randomized trial found that PEG and lactulose produced similar overall response rates, but PEG led to better symptom improvement scores and fewer side effects like vomiting and diarrhea.6PubMed. Polyethylene glycol compared to lactulose for constipation in pregnancy: A randomized controlled trial Switching to PEG is a reasonable first move, and since it’s available without a prescription in most countries, you don’t necessarily need a specialist to try it.
Prescription Options When Over-the-Counter Laxatives Aren’t Enough
When both lactulose and PEG have failed, prescription medications enter the picture. Prucalopride is a prokinetic drug that stimulates the muscles of the colon to contract more effectively. A systematic review and meta-analysis found that prucalopride was effective specifically in people whose chronic constipation had resisted conventional laxatives, including lactulose, senna, bisacodyl, and macrogol.7PubMed Central. Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials It’s particularly relevant for patients with slow-transit constipation, including those who have developed tolerance to stimulant laxatives over time.8PubMed Central. Prucalopride: the evidence for its use in the treatment of chronic constipation
Another class, secretagogue laxatives (which include linaclotide and lubiprostone), works by increasing fluid secretion into the intestine rather than just pulling water in osmotically. These are sometimes considered when patients struggle with adherence to the frequent dosing and large volumes of over-the-counter osmotic laxatives.9PubMed Central. Secretagogue laxatives as a potential strategy to overcome adherence barriers to over-the-counter treatment for clozapine-induced constipation Evidence supporting secretagogues specifically as replacements for failed lactulose is limited, but they represent a mechanistically different approach, which matters when one mechanism hasn’t worked.
Biofeedback for Pelvic Floor Dyssynergia
If the reason lactulose isn’t working is that your pelvic floor muscles aren’t cooperating during bowel movements, biofeedback therapy is the treatment with the strongest evidence behind it. Biofeedback teaches you to recognize and correct the paradoxical tightening of your pelvic floor. Randomized controlled trials in adults have shown it to be more effective than laxatives, sham biofeedback, and skeletal muscle relaxant drugs for dyssynergic defecation.10PubMed Central. Biofeedback therapy for dyssynergic defecation
The benefits hold up over time. In a randomized trial that followed patients for a year, those who received biofeedback had significant improvements in spontaneous bowel movements, normalization of their dyssynergia pattern, and faster colonic transit, while a standard-therapy comparison group did not improve on those measures.11PubMed Central. Long-term efficacy of biofeedback therapy for dyssynergic defecation: randomized controlled trial Access has traditionally been limited because biofeedback typically requires visits to a specialized center, but a randomized trial found that home-based biofeedback was equally effective as office-based sessions, with about 70% of patients classified as responders in both groups.12PubMed Central. Home-based versus office-based biofeedback therapy for constipation with dyssynergic defecation: a randomised controlled trial
A cost-effectiveness analysis found that when laxatives fail, the most economical strategy is to perform upfront anorectal function testing to figure out whether dyssynergia is present, and then refer the appropriate patients to pelvic floor physical therapy.13PubMed Central. Optimizing the Management Algorithm for Adults With Functional Constipation Failing a Fiber/Laxative Trial in General Gastroenterology: Cost-Effectiveness and Cost-Minimization Analysis If your doctor hasn’t tested for dyssynergia and you’ve failed laxative therapy, asking for this evaluation is a concrete next step worth pursuing.
When Lactulose Fails for Hepatic Encephalopathy
Lactulose is the backbone of treatment for hepatic encephalopathy, a condition in which liver disease causes toxins like ammonia to build up and impair brain function. The drug works by lowering colonic pH below about 6.2, which causes ammonia to shift from the blood into the colon, where it gets trapped as ammonium ions and expelled in stool.14PubMed Central. Lactulose in cirrhosis: Current understanding of efficacy, mechanism, and practical considerations When it “stops working,” the problem is often not that the drug itself has failed but that something else is driving the encephalopathy.
Infections are the most common precipitant. In one study of 132 patients hospitalized with hepatic encephalopathy, nearly half had an underlying infection, with spontaneous bacterial peritonitis, respiratory tract infections, and urinary tract infections being the most frequent culprits. Electrolyte disturbances were present in about 40% of patients, and constipation itself was found in a third.15PubMed Central. Precipitating Factors and Treatment Outcomes of Hepatic Encephalopathy in Liver Cirrhosis Gastrointestinal bleeding, dehydration, and malnutrition have also been identified as precipitating factors.16PubMed Central. Old and New Precipitants in Hepatic Encephalopathy: A New Look at a Field in Continuous Evolution If any of these are present, treating the trigger is often more important than adjusting the lactulose.
The Adherence Problem
A surprisingly common reason lactulose “doesn’t work” for hepatic encephalopathy is that patients aren’t able to take it consistently. This isn’t a failure of willpower. Lactulose tastes terrible, requires large volumes, causes cramping and diarrhea, and needs to be taken multiple times a day. A study that directly compared adherent and non-adherent patients found that the barriers reported more often by non-adherent patients included the large volume of lactulose, high dosing frequency, difficulty remembering doses, the unpleasant taste, and side effects.17PubMed Central. Barriers to Lactulose Adherence in Patients with Cirrhosis and Hepatic Encephalopathy
In another study using multivariable analysis, the factors most strongly linked to poor adherence were inadequate knowledge about hepatic encephalopathy, low educational level, and lactulose-related side effects.18PubMed Central. Understanding Hepatic Encephalopathy: Patient Knowledge, Adherence, and Barriers to Care in Cirrhosis Inadequate knowledge had the strongest association, suggesting that when patients or caregivers understand why lactulose matters and what it’s doing, they’re more likely to keep taking it. If you’re a caregiver and the person you’re looking after keeps skipping doses, the issue might not be stubbornness. It might be that the side effects are genuinely intolerable, or that the purpose of the medication was never adequately explained.
Adding Rifaximin for Hepatic Encephalopathy
The single most important escalation when lactulose alone isn’t controlling hepatic encephalopathy is adding rifaximin, a non-absorbable antibiotic that works in the gut. A landmark trial published in the New England Journal of Medicine found that rifaximin cut the risk of a breakthrough hepatic encephalopathy episode roughly in half compared to placebo, with breakthrough episodes occurring in about 22% of the rifaximin group versus 46% of the placebo group over six months. Over 90% of patients in both groups were also taking lactulose.19PubMed. Rifaximin Treatment in Hepatic Encephalopathy
A meta-analysis pooling seven randomized trials confirmed that the combination of rifaximin plus lactulose was associated with a higher rate of clinical improvement and lower mortality compared to lactulose alone.20PubMed Central. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis The combination has also been studied specifically in patients who developed hepatic encephalopathy after a TIPS procedure (a surgically created shunt in the liver), where it prevented recurrence significantly more effectively than lactulose alone or no medication.21PubMed Central. Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin If you or someone you care for is on lactulose alone and still having encephalopathy episodes, asking the hepatologist about adding rifaximin is the most evidence-backed next step.
Lactulose Enemas and PEG in Acute Episodes
During a severe episode of hepatic encephalopathy, especially when a patient can’t swallow or is confused, oral lactulose may not be practical. Lactulose retention enemas offer an alternative route. A randomized study found that patients who received both oral and rectal lactulose showed improvement about 48 hours sooner than those who received oral lactulose alone.22PubMed Central. Effect of rectal lactulose administration with oral therapy on time to recovery from hepatic encephalopathy: a randomized study In another study of patients with severe (grade 3 or 4) hepatic encephalopathy treated with lactulose retention enemas, 80% had complete reversal at 24 hours and 90% at 48 hours.23International Journal of Basic & Clinical Pharmacology. Effectiveness and safety of lactulose retention enema in cirrhotic patients with grade 3 or grade 4 hepatic encephalopathy
PEG has also emerged as a contender for acute hepatic encephalopathy. A small but striking trial found that patients who received PEG had faster resolution of encephalopathy than those on standard lactulose therapy, with a median resolution time of one day versus two days.24PubMed Central. Lactulose vs Polyethylene Glycol 3350-Electrolyte Solution for Treatment of Overt Hepatic Encephalopathy A subsequent systematic review and meta-analysis confirmed that PEG produced significantly lower encephalopathy scores at 24 hours and faster time to resolution compared to lactulose.25BMJ. Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis PEG isn’t yet standard of care for this purpose, but the data are accumulating, and in a hospital setting where lactulose isn’t producing results quickly enough, it may be worth discussing.
Other Adjunct Therapies for Hepatic Encephalopathy
Beyond rifaximin, a few other approaches have shown promise. L-ornithine L-aspartate (LOLA) helps the body metabolize ammonia through alternative biochemical pathways. A randomized controlled trial of ICU patients with overt hepatic encephalopathy found that adding LOLA to branched-chain amino acids and conventional therapy led to significant neurological improvement, with nearly 90% of patients experiencing improvement or resolution of their encephalopathy.26QJM: An International Journal of Medicine. Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients with Hepatic Encephalopathy: A Randomized Controlled Trial
Fecal microbiota transplantation (FMT) is an emerging area of research that aims to restore a healthier balance of gut bacteria, which could reduce ammonia production at its source.27PubMed Central. Role of fecal microbiota transplant in management of hepatic encephalopathy: Current trends and future directions This is still experimental, but it represents a fundamentally different strategy from trying to clear ammonia after it’s already been produced.
For patients whose encephalopathy is driven by large portosystemic shunts (abnormal blood vessels that divert blood around the liver), embolization of those shunts can be effective. A meta-analysis found that shunt embolization significantly reduced encephalopathy recurrence in patients with cirrhosis-related portosystemic shunts.28PubMed Central. Effects of shunt embolization on hepatic encephalopathy recurrence in patients with major portosystemic shunts: A systematic review and meta-analysis This is a procedure reserved for patients who’ve failed maximum medical therapy, but case series have described it as either complementary or curative for patients who remain encephalopathic despite lactulose and rifaximin.29Journal of Vascular and Interventional Radiology. Embolotherapy for Hepatic Encephalopathy Caused by Spontaneous Portosystemic Shunts
Safety Concerns With Escalating Lactulose Doses
When lactulose isn’t producing results, the instinct to keep increasing the dose can create its own problems. Lactulose is an osmotic agent, meaning it pulls water into the colon. Too much of it causes diarrhea, and the resulting water loss can exceed the amount of sodium lost, leading to dangerously elevated sodium levels. A study of 75 courses of lactulose therapy found that high sodium levels developed in about a quarter of treatment courses, and mortality was nearly three times higher in patients who became hypernatremic compared to those who didn’t.30PubMed. Hypernatremia and lactulose therapy This risk is most relevant in hospitalized patients and those with liver disease, but it’s a reminder that “more lactulose” is not always better. If the current dose isn’t working, the solution is usually to investigate why or to add a different treatment, not to keep pushing the dose upward without monitoring.
Excessive lactulose also causes the very symptoms that make patients stop taking it: bloating, cramping, and explosive diarrhea. For people taking lactulose for hepatic encephalopathy, overshooting the dose target can lead to dehydration, which ironically is itself a precipitant of the very condition you’re trying to treat. The sweet spot for hepatic encephalopathy remains two to three soft stools per day. More than that usually means the dose is too high, and the side effects will eventually undermine adherence, creating a vicious cycle.
Getting the Right Diagnostic Workup
If you’ve been taking lactulose for constipation and it genuinely isn’t helping despite adequate dosing and enough time, the evidence points toward pursuing specific testing rather than cycling through more laxatives at random. Anorectal manometry and a balloon expulsion test can identify pelvic floor dyssynergia. A colonic transit study can determine whether your colon moves contents at a normal speed. These tests change the treatment path in meaningful ways: dyssynergia points toward biofeedback, slow transit points toward prokinetics like prucalopride, and the presence of an underlying medical condition or offending medication points toward addressing that root cause.
For hepatic encephalopathy, when lactulose plus rifaximin isn’t enough, the workup might include imaging to look for large portosystemic shunts, blood cultures or paracentesis to rule out infection, and careful review of electrolytes and renal function. The key insight is the same for both conditions: lactulose is a tool, not a diagnosis. When the tool doesn’t work, the question should shift from “what’s wrong with the tool” to “what’s actually going on.”